Sulforadex
- Generic Name
- Sulforadex
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Neoplasm
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- Evgen Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT02970682
- Locations
- 🇧🇪
Grand Hopital de Charleroi, Service D'Oncologie-Hematologie, Charleroi, Belgium
🇧🇪Saint-Luc hospital, Brussels, Woluwe-Saint-Lambert, Belgium
🇫🇷ICO René Gauducheau, St Herblain, Nantes, Loire Atlantique, France
SFX-01 After Subarachnoid Haemorrhage
Phase 2
Completed
- Conditions
- Subarachnoid Hemorrhage, Spontaneous
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Evgen Pharma
- Target Recruit Count
- 90
- Registration Number
- NCT02614742
- Locations
- 🇬🇧
Western General Hospital, Edinburgh, United Kingdom
🇬🇧Southampton General Hospital, Southampton, Hampshire, United Kingdom
🇬🇧The Royal London Hospital, London, United Kingdom
Sulforadex in Healthy Human Males MAD
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Evgen Pharma
- Target Recruit Count
- 18
- Registration Number
- NCT02055716
- Locations
- 🇬🇧
Richmond Pharmacology Limited, London, United Kingdom
Sulforadex in Healthy Volunteers SAD
Phase 1
Completed
- Conditions
- Stage, Prostate Cancer
- Interventions
- Drug: Alpha cyclodextrin
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Evgen Pharma
- Target Recruit Count
- 29
- Registration Number
- NCT01948362
- Locations
- 🇬🇧
Richmond Pharmacology, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath